A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of 
BMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell Lung 
Cancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies

Lungentumoren

Nicht-kleinzelliges Bronchialkarzinom (NSCLC)

RAF (rapidly accelerated fibrosarcoma)

BRAF

EGFR

HER2/neu

ras-Gen

KRAS

NTRK

RET (Rezeptor-Tyrosinkinase)

ROS-1 (c-ros oncogene 1, receptor tyrosine kinase)

Phase II

BMS-CA240-0009

Zweitlinie

Drittlinie

<p class="MsoNormal">A Phase 2, Open-Label, Parallel Cohort Study of
Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or
Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]</p>